At the end of healthy weight week and when New Year resolutions are kicking in, it is timely to review the safety of the three scheduled medications available in Australia with an indication for obesity. It should be noted that with all medications (orlistat, phentermine and sibutramine), lifestyle changes (such as increasing physical activity and reducing calorie intake) remain the cornerstone of management. None of these medications should be used routinely by patients with a Body Mass Index (BMI) of less than 30 (or 25 to 27 in special circumstances). In addition, phentermine is indicated for short term use only.
Safety Issues with Drugs Used in Obesity Management: RGH E-Bulletin
Additional comments powered by BackType
Previous post: Practical Pharmacy: Stock Control
Next post: RGH E-Bulletin: Drug-Induced Myopathies




{ 1 trackback }
{ 0 comments… add one now }